Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 1, 2016, Pages e1-e2

  Diamandis, Eleftherios P ^a,b   Plebani, Mario ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

biomarker; glypican 1; pancreatic cancer

Indexed keywords

GLYPICAN 1; GLYPICAN;

CANCER DIAGNOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; HUMAN; LETTER; PANCREAS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; ANIMAL; FEMALE; MALE; METABOLISM; PANCREATIC NEOPLASMS;

ANIMALS; EXOSOMES; FEMALE; GLYPICANS; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 84954326609     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0773     Document Type: Letter

References (4)

1. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015;523:177-82.
2. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004:96;353-6.
3. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010:102;1462-7.
4. Lippi G, Plebani M. Personalized medicine: moving from simple theory to daily practice. Clin Chem Lab Med 2015;53:959-60.